LIXTE BIOTECHNOLOGY HOLDINGS, INC. Segments Disclosure
| 10. | Segment Information |
The Company’s chief operating decision maker (“CODM”) has been identified as the Company’s President and Chief Executive Officer (“CEO”). The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it has a single operating segment composed of the consolidated financial results of the Company.
The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs.
| Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash based compensation | 751,860 | 753,124 | ||||||
| Stock-based compensation | 1,388,322 | 418,422 | ||||||
| Patent and licensing legal and filing fees and costs | 112,091 | 243,186 | ||||||
| Other consulting and professional fees | 1,431,118 | 735,021 | ||||||
| Insurance expense | 257,478 | 434,444 | ||||||
| Other costs and expenses, net | 911,833 | 262,360 | ||||||
| Total general and administrative costs | $ | 4,852,702 | $ | 2,846,557 | ||||
The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in research and development costs.
| Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Clinical and related oversight costs | $ | 57,193 | $ | 377,958 | ||||
| Preclinical research focused on development of additional novel anti-cancer compounds | 188,675 | 329,438 | ||||||
| Regulatory service costs | 9,051 | 18,836 | ||||||
| Total research and development costs | $ | 254,919 | $ | 726,232 | ||||
The following table presents a summary of research and development costs for the years ended December 31, 2025 and 2024 based on the respective geographical regions where such costs were incurred.
| Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| United States | $ | 193,679 | $ | 462,566 | ||||
| Spain | 61,240 | 51,022 | ||||||
| China | 2,282 | |||||||
| Netherlands | 210,362 | |||||||
| Total | $ | 254,919 | $ | 726,232 | ||||
The following table presents the Company’s total assets by segment at December 31, 2025 and 2024.
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development assets | $ | 10,000 | $ | 39,298 | ||||
| Corporate assets | 12,723,621 | 1,106,205 | ||||||
| Total assets | $ | 12,733,621 | $ | 1,145,503 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 31, 2026 | Showing above |
| 2024 | Mar 24, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.